<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126528</url>
  </required_header>
  <id_info>
    <org_study_id>JHU-IRB2481</org_study_id>
    <secondary_id>02829-5</secondary_id>
    <nct_id>NCT01126528</nct_id>
  </id_info>
  <brief_title>Antenatal Vitamin D3 Supplementation in Bangladesh: Randomized Controlled Trial</brief_title>
  <acronym>AViDD-2</acronym>
  <official_title>The Effect of Antenatal Vitamin D Supplementation on Maternal-fetal Vitamin D Status and Neonatal Immune Function: a Randomized Controlled Trial in Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized placebo-controlled trial of oral weekly vitamin D3
      (cholecalciferol) supplementation during the third trimester of pregnancy among women in
      Dhaka, Bangladesh. The overall goal of the study is to establish whether there is evidence
      that improving vitamin D status among pregnant women in Bangladesh will enhance the
      resistance of the infant offspring to infection.

      The aims of the study are to assess the effect of supplementation on 1) maternal and infant
      vitamin D status (based on blood concentrations of a vitamin D metabolite) and, 2) markers of
      neonatal immune function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aims of this study are:

      AIM #1 - To assess the effect of weekly antenatal administration of oral vitamin D3 (875
      mcg/week = 35,000 IU week â‰ˆ 5,000 IU per day) started in the third trimester (26-29 weeks
      gestation) on maternal vitamin D status and fetal-neonatal vitamin D status (cord blood), in
      comparison to a placebo control supplement.

      AIM #2 - To demonstrate the maternal and fetal safety of weekly maternal antenatal (second
      and third-trimester) vitamin D supplementation at a dose of 875 mcg/week by monitoring
      maternal serum calcium, urinary calcium excretion, cord blood calcium concentration, and
      newborn clinical parameters.

      AIM #3 - To measure the effect of antenatal vitamin D supplementation on selected biomarkers
      of fetal-neonatal immune function in cord blood: in vitro stimulated cord blood mononuclear
      cell (CBMC) LL-37 expression, gene expression related to inflammatory and immunoregulatory
      pathways, Th1/Th2 cytokine secretion, and bactericidal properties.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25-hydroxyvitamin D concentration</measure>
    <time_frame>Maternal: during 3rd trimester; Neonatal (cord blood)</time_frame>
    <description>Biomarker of vitamin D status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>Maternal:3rd trimester; Cord blood.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Ca:Cr ration</measure>
    <time_frame>Maternal- 3rd trimester</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal immune function</measure>
    <time_frame>Cord blood</time_frame>
    <description>Selected markers of innate and adaptive immunity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant growth</measure>
    <time_frame>Postnatal observational follow-up phase</time_frame>
    <description>Infant growth parameters during postnatal follow-up, up to 12 months of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant and maternal postnatal vitamin D status</measure>
    <time_frame>Postnatal observational follow-up phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal serum calcium</measure>
    <time_frame>1st week postnatal</time_frame>
    <description>Infant serum calcium during the first week postnatal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 (cholecalciferol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>35,000 IU per week, started at 26-29 weeks gestation, until delivery.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>Cholecalciferol; Vigantol Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 to &lt;35 years.

          -  Current residence in Dhaka at a fixed address

          -  Plans to have the delivery performed at the Shimantik maternity center, and to stay in
             Dhaka throughout the pregnancy and for at least one month past the date of delivery.

          -  Gestational age of 26th to 29th (inclusive), estimated based on the first day of the
             last menstrual period (LMP).

        Exclusion Criteria:

          -  Use of any dietary supplement containing more than 400 IU/day (10 mcg/day) of vitamin
             D within the month prior to enrolment, or refusal to stop taking supplemental vitamin
             D at any dose after enrollment.

          -  Current use of anti-convulsant or anti-mycobacterial (tuberculosis) medications.

          -  Severe anemia (hemoglobin concentration &lt; 70 g/L).

          -  Complicated medical or obstetric history that may increase the risk of preterm birth
             or labor/delivery complications, based on self-report or clinical assessment by
             physician (e.g., cardiovascular disease, uterine hemorrhage, placenta previa,
             threatened abortion, hypertension, preeclampsia, preterm labor, or multiple
             gestation).

          -  Prior history of delivery of an infant with a major congenital anomaly, birth
             asphyxia, or perinatal death (stillbirth or death within first week of life).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullah Baqui, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>JHSPH; ICDDR,B</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rubhana Raqib, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoeal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B)</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Abdullah Baqui</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Developing countries</keyword>
  <keyword>Bangladesh</keyword>
  <keyword>Infant, Newborn</keyword>
  <keyword>Reproductive Health</keyword>
  <keyword>Infant, Newborn, Diseases</keyword>
  <keyword>Perinatology</keyword>
  <keyword>Immunology</keyword>
  <keyword>cathelicidin</keyword>
  <keyword>Maternal Nutrition Physiology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

